CAMBRIDGE, Mass. , April 5, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will hold its inaugural Research & Development Day for analysts and the investor community on Thursday, April 11, 2013 from 9:30 a.m. to 1:00 p.m. ET .
CAMBRIDGE, Mass. , April 4, 2013 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with erlotinib to treat
CAMBRIDGE, Mass. , March 18, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the last patient has been enrolled in a Phase 2, open-label, randomized clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with
Enters 2013 With Six Novel Therapeutic Candidates in Clinical Development, Including Phase 3 and Phase 2 Trials in Multiple Cancer Indications Progress Made in 2012 Puts Merrimack in Position for Robust Set of Milestones in 2013 CAMBRIDGE, Mass. , March 14, 2013 (GLOBE NEWSWIRE) -- Merrimack
CAMBRIDGE, Mass. , Feb. 27, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Fourth Quarter 2012 Investor Conference Call and webcast at 10 a.m., Eastern time , on Thursday, March 14 .
CAMBRIDGE, Mass. , Feb. 25, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy , President & CEO, is scheduled to present at the Cowen and Company 33 rd Annual Health Care Conference on Wednesday, March 6, 2013 at 8:00 a.m.
CAMBRIDGE, Mass. , Feb. 7, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Peter Laivins , Vice President of Late Stage Clinical Development and Project Leader for MM-398, will serve as a panelist in the "Oncology: Pancreatic Cancer" panel at the BIO CEO